InsidersTradesSigma
THX PHARMA Stock: price and insider trades · France · AMF
Track the THX PHARMA share price and the full directors' dealings record of the company, a listed issuer based in France. Shares are listed on FR FR, under the supervision of AMF. Operating in the Healthcare & Pharma sector, THX PHARMA has logged 2 insider filings. Market capitalisation: €53.1m. The latest transaction was filed on 2 April 2026 (Acquisition). Among the most active insiders: JULIEN VEYS. The full history is accessible without an account.
2
Insider Decl.
0
Thresholds
€14,669
1 ops.
Buy Volume
·
0 ops.
Sell Volume
40Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 April 2026
Declarations2 total
4,944 shares@ €2.96710.029% mcap100.0% of flowOption d'achatEuronext Growth Paris2026DD1105382
Ideal exit: 11 Dec 2026 (T+270)
22,436 shares@ €3.02250.13% mcap100.0% of flowLevée vente BSPCEEuronext Growth Paris2026DD1104316
2 of 2 declarations
About THX PHARMA
THX Pharma, formerly known as Theranexus, is a French biopharmaceutical company listed on Euronext Growth Paris under ISIN FR0013286259 and ticker ALTHX. The company is rooted in the French public research ecosystem, having emerged from the CEA, and is headquartered in Lyon. It focuses on rare neurological diseases, a highly specialized therapeutic area defined by significant unmet medical needs, limited treatment options, and substantial value-creation potential for successful drug developers. THX Pharma has built its identity around innovative approaches designed to address the interaction between neurons and glial cells, alongside a broader platform dedicated to identifying and characterizing drug candidates for rare neurological disorders. The company was co-founded in March 2013 by scientists connected to the CEA neuroscience environment, reflecting a strong science-to-clinic origin story and a deep research heritage. Its current portfolio is centered on two main assets. Batten-1 is the lead program and targets juvenile Batten disease (CLN3), an ultra-rare pediatric neurodegenerative disorder. TX01 is an adapted oral formulation of an already approved active ingredient, developed for Gaucher disease type 1 and Niemann-Pick disease type C, two rare lysosomal diseases with important unmet needs. THX Pharma also owns an antisense oligonucleotide platform, co-developed with leading laboratories, which broadens its innovation capabilities in rare neurological indications. A key recent milestone came in February 2026, when THX Pharma signed a strategic licensing agreement with Biocodex. Under the deal, Biocodex acquired an exclusive global license for Batten-1 and an exclusive license for TX01 in the United States and Canada, for a total potential value of up to €173 million, including upfront, development, and commercialization payments. This agreement materially strengthens the company’s industrial validation and underlines the strategic attractiveness of its pipeline. THX Pharma remains closely involved in the scientific and clinical advancement of Batten-1, including the preparation of a phase 3 trial, while leveraging partners to support future commercialization. Overall, THX Pharma occupies a focused niche in rare neurology, combining French research roots, a selective development model, and international partnering potential.
